Benefit of switching to mepolizumab from omalizumab in severe eosinophilic asthma based on patient characteristics

to related objects

Location: Deutsche Nationalbibliothek Frankfurt am Main

ISSN: 1465-993X

Extent: Online-Ressource

Language: Englisch

Notes: online resource.

Bibliographic citation: Benefit of switching to mepolizumab from omalizumab in severe eosinophilic asthma based on patient characteristics ; volume:22 ; number:1 ; day:10 ; month:5 ; year:2021 ; pages:1-13 ; date:12.2021
Respiratory research ; 22, Heft 1 (10.5.2021), 1-13, 12.2021

Creator: Liu, Mark C.
Chipps, Bradley
Munoz, Xavier
Devouassoux, Gilles
Bergna, Miguel
Smith, Steven G.
Price, Robert G.
Galkin, Dmitry V.
Azmi, Jay
Mouneimne, Dalal
Albers, Frank C.
Chapman, Kenneth R.

Contributor: SpringerLink (Online service)

DOI: 10.1186/s12931-021-01733-9

URN: urn:nbn:de:101:1-2021091121433113533916

Rights: Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.

Last update: 15.08.2025, 7:26 AM CEST

Data provider

This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.

Show original at data provider

Associated

Liu, Mark C.
Chipps, Bradley
Munoz, Xavier
Devouassoux, Gilles
Bergna, Miguel
Smith, Steven G.
Price, Robert G.
Galkin, Dmitry V.
Azmi, Jay
Mouneimne, Dalal
Albers, Frank C.
Chapman, Kenneth R.
SpringerLink (Online service)

Other Objects (12)

Omalizumab therapy in a 13-year-old boy with severe persistent asthma and concomitant eosinophilic esophagitis

Severe asthma and the omalizumab option

4-month omalizumab efficacy outcomes for severe allergic asthma: the Dutch National Omalizumab in Asthma Registry

Omalizumab Transitions in Severe Asthma: Factors Influencing Switching Decisions and Timing for Optimal Response

Eosinophilic bioactivities in severe asthma

Successful management of severe asthma in a young boy with eosinophilic chronic rhinosinusitis who received omalizumab: a case report

Identifying clinical and demographic characteristic differences between eosinophilic and non-eosinophilic asthma and detecting predictors of eosinophilic asthma among Egyptian asthmatic patients

Emerging Biological Therapies in Severe Eosinophilic Asthma

Omalizumab in patients with severe asthma and persistent sputum eosinophilia

Omalizumab-Therapie bei Jugendlichen mit schwerem allergischen Asthma – eine Anwendungsbeobachtung

Omalizumab-Therapie bei Jugendlichen mit schwerem allergischem Asthma – eine Anwendungsbeobachtung

Dermatomyositis associated with omalizumab therapy for severe asthma: a case report

Omalizumab therapy in a 13-year-old boy with severe persistent asthma and concomitant eosinophilic esophagitis

Severe asthma and the omalizumab option

4-month omalizumab efficacy outcomes for severe allergic asthma: the Dutch National Omalizumab in Asthma Registry

Omalizumab Transitions in Severe Asthma: Factors Influencing Switching Decisions and Timing for Optimal Response

Eosinophilic bioactivities in severe asthma

Successful management of severe asthma in a young boy with eosinophilic chronic rhinosinusitis who received omalizumab: a case report

Identifying clinical and demographic characteristic differences between eosinophilic and non-eosinophilic asthma and detecting predictors of eosinophilic asthma among Egyptian asthmatic patients

Emerging Biological Therapies in Severe Eosinophilic Asthma

Omalizumab in patients with severe asthma and persistent sputum eosinophilia

Omalizumab-Therapie bei Jugendlichen mit schwerem allergischen Asthma – eine Anwendungsbeobachtung

Omalizumab-Therapie bei Jugendlichen mit schwerem allergischem Asthma – eine Anwendungsbeobachtung

Dermatomyositis associated with omalizumab therapy for severe asthma: a case report

Omalizumab therapy in a 13-year-old boy with severe persistent asthma and concomitant eosinophilic esophagitis

Severe asthma and the omalizumab option

4-month omalizumab efficacy outcomes for severe allergic asthma: the Dutch National Omalizumab in Asthma Registry

Omalizumab Transitions in Severe Asthma: Factors Influencing Switching Decisions and Timing for Optimal Response

Eosinophilic bioactivities in severe asthma

Successful management of severe asthma in a young boy with eosinophilic chronic rhinosinusitis who received omalizumab: a case report

Identifying clinical and demographic characteristic differences between eosinophilic and non-eosinophilic asthma and detecting predictors of eosinophilic asthma among Egyptian asthmatic patients

Emerging Biological Therapies in Severe Eosinophilic Asthma

Omalizumab in patients with severe asthma and persistent sputum eosinophilia

Omalizumab-Therapie bei Jugendlichen mit schwerem allergischen Asthma – eine Anwendungsbeobachtung

Omalizumab-Therapie bei Jugendlichen mit schwerem allergischem Asthma – eine Anwendungsbeobachtung

Dermatomyositis associated with omalizumab therapy for severe asthma: a case report

Cultural heritage institutions wishing to register will find more information here.

Fields marked * need to be filled in.

Username*

Please enter your username

Email*

Please enter your email address

Please do not fill this field

First name

Last name

Password*

Please enter your password

Confirm password*

Please enter the same password

I have read the terms of use and the privacy policy for the collection of personal data and accept them. *

This field is required.

I would like to subscribe to the newsletter of the Deutsche Digitale Bibliothek. See newsletter subscription info.

Account created

Your "My DDB" account has been successfully created. Before you can log in to your account, you must click the confirmation link in the message we just sent to the email address you provided.

Benefit of switching to mepolizumab from omalizumab in severe eosinophilic asthma based on patient characteristics

Object Details

References and Relationships

Contributors, Places and Time

Further information

Data provider

Associated

Other Objects (12)

Omalizumab therapy in a 13-year-old boy with severe persistent asthma and concomitant eosinophilic esophagitis

Severe asthma and the omalizumab option

4-month omalizumab efficacy outcomes for severe allergic asthma: the Dutch National Omalizumab in Asthma Registry

Omalizumab Transitions in Severe Asthma: Factors Influencing Switching Decisions and Timing for Optimal Response

Eosinophilic bioactivities in severe asthma

Successful management of severe asthma in a young boy with eosinophilic chronic rhinosinusitis who received omalizumab: a case report

Identifying clinical and demographic characteristic differences between eosinophilic and non-eosinophilic asthma and detecting predictors of eosinophilic asthma among Egyptian asthmatic patients

Emerging Biological Therapies in Severe Eosinophilic Asthma

Omalizumab in patients with severe asthma and persistent sputum eosinophilia

Omalizumab-Therapie bei Jugendlichen mit schwerem allergischen Asthma – eine Anwendungsbeobachtung

Omalizumab-Therapie bei Jugendlichen mit schwerem allergischem Asthma – eine Anwendungsbeobachtung

Dermatomyositis associated with omalizumab therapy for severe asthma: a case report

Omalizumab therapy in a 13-year-old boy with severe persistent asthma and concomitant eosinophilic esophagitis

Severe asthma and the omalizumab option

4-month omalizumab efficacy outcomes for severe allergic asthma: the Dutch National Omalizumab in Asthma Registry

Omalizumab Transitions in Severe Asthma: Factors Influencing Switching Decisions and Timing for Optimal Response

Eosinophilic bioactivities in severe asthma

Successful management of severe asthma in a young boy with eosinophilic chronic rhinosinusitis who received omalizumab: a case report

Identifying clinical and demographic characteristic differences between eosinophilic and non-eosinophilic asthma and detecting predictors of eosinophilic asthma among Egyptian asthmatic patients

Emerging Biological Therapies in Severe Eosinophilic Asthma

Omalizumab in patients with severe asthma and persistent sputum eosinophilia

Omalizumab-Therapie bei Jugendlichen mit schwerem allergischen Asthma – eine Anwendungsbeobachtung

Omalizumab-Therapie bei Jugendlichen mit schwerem allergischem Asthma – eine Anwendungsbeobachtung

Dermatomyositis associated with omalizumab therapy for severe asthma: a case report

Omalizumab therapy in a 13-year-old boy with severe persistent asthma and concomitant eosinophilic esophagitis

Severe asthma and the omalizumab option

4-month omalizumab efficacy outcomes for severe allergic asthma: the Dutch National Omalizumab in Asthma Registry

Omalizumab Transitions in Severe Asthma: Factors Influencing Switching Decisions and Timing for Optimal Response

Eosinophilic bioactivities in severe asthma

Successful management of severe asthma in a young boy with eosinophilic chronic rhinosinusitis who received omalizumab: a case report

Identifying clinical and demographic characteristic differences between eosinophilic and non-eosinophilic asthma and detecting predictors of eosinophilic asthma among Egyptian asthmatic patients

Emerging Biological Therapies in Severe Eosinophilic Asthma

Omalizumab in patients with severe asthma and persistent sputum eosinophilia

Omalizumab-Therapie bei Jugendlichen mit schwerem allergischen Asthma – eine Anwendungsbeobachtung

Omalizumab-Therapie bei Jugendlichen mit schwerem allergischem Asthma – eine Anwendungsbeobachtung

Dermatomyositis associated with omalizumab therapy for severe asthma: a case report

Related objects

Reset password